Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Multiple Myeloma Monthly Minutes
Multiple Myeloma
First Results from a Phase 1 Study of BMS-986393, a GPRC5D-Targeted CAR T-Cell Therapy, in Patients with RRMM
Multiple Myeloma
Preliminary data support the use of BMS-986393 in patients with RRMM despite prior BCMA-directed therapy.
Read More ›
GC012F, an Autologous BCMA and CD19 Dual-Targeting CAR T-Cell Therapy, as First-Line Treatment for Transplant-Eligible Patients with Newly Diagnosed High-Risk Multiple Myeloma
Multiple Myeloma
A phase 1 trial of GC012F demonstrated an overall response rate of 100% in high-risk, transplant-eligible patients with newly diagnosed multiple myeloma.
Read More ›
Updated Results from IKEMA Demonstrate a Median PFS of Nearly 3 Years with Isa-Kd
Multiple Myeloma
Updated results from the IKEMA trial show a superior benefit with isatuximab + carfilzomib and dexamethasone versus carfilzomib and dexamethasone alone in patients with RRMM.
Read More ›
Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma with No Prior BCMA-Targeted Treatment: Results from MagnetisMM-3
Multiple Myeloma
Results from cohort A of MagnetisMM-3 showed promising efficacy and a tolerable safety profile with elranatamab in RRMM patients naïve to BCMA-targeted treatment.
Read More ›
Patient-Reported Outcomes of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone
Multiple Myeloma
Results of patient-reported outcomes from the GRIFFIN study showed improved health-related quality of life in patients with NDMM with the addition of daratumumab to lenalidomide, bortezomib, and dexamethasone.
Read More ›
Tecvayli, First Bispecific BCMA-Directed CD3 T-Cell Engager, Received FDA Approval for Relapsed or Refractory Multiple Myeloma
FDA Approvals, News & Updates
,
Multiple Myeloma
On
October 25, 2022
, the FDA accelerated the approval of teclistamab-cqyv (Tecvayli; Janssen Biotech), the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory multiple myeloma who received ≥4 previous lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody.
Read More ›
Real-Life Use of Isatuximab plus Pomalidomide and Dexamethasone Supports Standard of Care in Patients with RRMM
Multiple Myeloma
Data from the IMAGE study support real-world use of isatuximab in patients with relapsed/refractory multiple myeloma, with findings similar to those reported for ICARIA-MM.
Read More ›
HRQOL with Cilta-Cel Infusion for RRMM: Results from CARTITUDE-1
Multiple Myeloma
Patient-reported outcomes with ciltacabtagene autoleucel are consistent with clinical findings and support its use in heavily pretreated patients with relapsed/refractory multiple myeloma.
Read More ›
Iberdomide plus Dexamethasone Showed Clinically Meaningful Activity in Heavily Pretreated Late-Line Patients with RRMM
Multiple Myeloma
Iberdomide, a novel cereblon E3 ligase modulator, in combination with dexamethasone showed encouraging results in a multicohort, open-label, phase 1/2 trial.
Read More ›
Novel CELMoD Agents for Multiple Myeloma
Multiple Myeloma
Iberdomide and mezigdomide have shown to be more potent than traditional immunomodulators and may have potential as new oral agents in multiple myeloma.
Read More ›
Page 1 of 13
1
2
3
4
5
6
7
8
9
10
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes